RxDoctor Payments Data

John Tulloch, MD

Cardiovascular Disease · Tulsa, OKNPI 1740336486

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,355 of the $7,956 with a category attached, or 79.9%. 13 manufacturers reported payments, led by Abbott at 37.7% of the total.

$7,956in general payments, 2019–2025

Across 80 payments — averaging $99.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Edwards Lifesciences$2K
  • Ancora Heart, Inc.$2K
  • Heartflow, Inc.$123
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
  • Lantheus Medical Imaging, Inc.$83
  • plus $218 from 7 others

What the payments were for

  • Travel & lodging$6,35580%
  • Food & beverage$1,57920%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,956 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$282,823
Medicare patients
2,953
Services billed
4,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$162,979
EntrestoSacubitril/Valsartan100$113,370
JardianceEmpagliflozin55$44,329
XareltoRivaroxaban42$44,061
BrilintaTicagrelor43$29,108
Repatha SureclickEvolocumab21$11,860
Atorvastatin Calcium196$2,787
Metoprolol Succinate149$2,500
Rosuvastatin Calcium143$2,178
Ranolazine ErRanolazine29$1,612
Nebivolol Hcl24$1,347
Ezetimibe80$1,260
Carvedilol94$1,004
Gabapentin15$841
Metoprolol Tartrate110$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$162,979199 claims
NovartisEntresto$12$113,370100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →